Organon & (OGN) Financials: Revenue & Earnings
OGN$13.81+0.03 +0.18%
$3.63B
Market Cap
17.41
P/E
4.12
Forward P/E
47
Score
Organon & (OGN) Financials: Revenue & Earnings
OGN price $13.81 +0.03 +0.18%
- Ticker
- OGN
- Price
- $13.81
- Change
- +0.03 +0.18%
- Market cap ?
- $3.63B
- P/E ?
- 17.41
- Forward P/E ?
- 4.12
- Dividend yield ?
- 0.58%
- Beta ?
- 1.54
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stocklytics score
- 47
- Value
- 75
- Quality
- 40
- Growth
- 25
Stocklytics score rationale: value 75, quality 40, growth 25.
Financials
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 10500000000 | 9777000000 | 7777000000 | 6532000000 | 6304000000 | 6174000000 | 6263000000 | 6403000000 | 6216000000 |
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis…
Earnings and financials
Organon & Co. (OGN) trades at $13.81, with a market cap of $3.63B and a trailing P/E of 17.41. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| 10500000000 | 9777000000 | 7777000000 | 6532000000 | 6304000000 | 6174000000 | 6263000000 | 6403000000 | 6216000000 |
Insights · Dividends · Forecast · Financials · Learn